JETEMA Co. Valuation Multiples

Discover JETEMA Co.'s revenue and EBITDA valuation multiples and investment history, alongside public comparables like CROSSJECT, Neuronetics, Optiscan Imaging, Paxman and more.

JETEMA Co. Overview

About JETEMA Co.

JETEMA Co Ltd is a bio venture company. It offers products such as Botulinum toxin, Filler, Anti-aging solutions. The company also offers medical devices and cosmetics.


Founded

2009

HQ

South Korea

Employees

N/A

Website

jetema.com

Financials (FY)

Revenue: $52M
EBITDA: $8M

EV

$186M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

JETEMA Co. Financials

JETEMA Co. reported last fiscal year revenue of $52M and EBITDA of $8M.

In the same fiscal year, JETEMA Co. generated $25M in gross profit, $8M in EBITDA, and had net loss of ($4M).

Revenue (LTM)


JETEMA Co. P&L

In the most recent fiscal year, JETEMA Co. reported revenue of $52M and EBITDA of $8M.

JETEMA Co. is unprofitable as of last fiscal year, with gross margin of 48%, EBITDA margin of 15%, and net margin of (9%).

See analyst estimates for JETEMA Co.
Last FY202320242025202620272028
Revenue$52M$39M$46M$52M
Gross Profit$25M$19M$22M$25M
Gross Margin48%48%49%48%
EBITDA$8M$15M$10M$8M
EBITDA Margin15%38%23%15%
EBIT Margin5%4%6%5%
Net Profit($4M)$9M($127K)($4M)
Net Margin(9%)24%(0%)(9%)
Net Debt$75M---

Financial data powered by Morningstar, Inc.

JETEMA Co. Stock Performance

JETEMA Co. has current market cap of $111M, and enterprise value of $186M.

Market Cap Evolution


JETEMA Co.'s stock price is $2.99.

JETEMA Co. share price decreased by 7.1% in the last 30 days, and by 34.6% in the last year.

JETEMA Co. has an EPS (earnings per share) of $-0.12.

See more trading valuation data for JETEMA Co.
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$186M$111M-0.5%-7.1%-36.7%-34.6%$-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

JETEMA Co. Valuation Multiples

JETEMA Co. trades at 3.6x EV/Revenue multiple, and 24.1x EV/EBITDA.

See NTM and 2027E valuation multiples for JETEMA Co.

EV / Revenue (LTM)


JETEMA Co. Financial Valuation Multiples

As of July 19, 2026, JETEMA Co. has market cap of $111M and EV of $186M.

JETEMA Co. has a P/E ratio of (25.1x).

Last FY202320242025202620272028
EV/Revenue3.6x4.7x4.0x3.6x
EV/EBITDA24.1x12.4x17.8x24.1x
EV/EBIT72.3x104.8x67.2x72.3x
EV/Gross Profit7.5x9.8x8.3x7.5x
P/E(25.1x)11.9xn/m(25.1x)
EV/FCF(57.5x)n/m(54.4x)(57.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified JETEMA Co. Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

JETEMA Co. Margins & Growth Rates

JETEMA Co. grew revenue by 18% and EBITDA by 98% in the last fiscal year.

In the most recent fiscal year, JETEMA Co. reported gross margin of 48%, EBITDA margin of 15%, and net margin of (9%).

See estimated margins and future growth rates for JETEMA Co.

JETEMA Co. Margins

Last FY202420252026202720282029
Gross Margin48%49%48%54%
EBITDA Margin15%23%15%25%
EBIT Margin5%6%5%15%
Net Margin(9%)(0%)(9%)2%
FCF Margin(6%)(7%)(6%)-

JETEMA Co. Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth18%17%12%18%
Gross Profit Growth32%18%10%32%
EBITDA Growth98%(31%)(26%)98%
EBIT Growth245%56%(7%)245%
Net Profit Growth(126%)(101%)3407%(126%)
FCF Growth-1449%(5%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

JETEMA Co. Operational KPIs

JETEMA Co.'s Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

JETEMA Co.'s Rule of X is 69% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for JETEMA Co.
Last FY202320242025202620272028
Rule of 4043%---
Bessemer Rule of X69%---
S&M Expenses to Revenue9%10%9%9%
G&A Expenses to Revenue3%2%3%3%
R&D Expenses to Revenue13%17%14%13%
Opex to Revenue43%44%43%43%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

JETEMA Co. Competitors

JETEMA Co. competitors include CROSSJECT, Neuronetics, Optiscan Imaging, Paxman, Vivani Medical, Medifast, IEVA Group, Beauty Health, Emvision and Onyx Healthcare.

Most JETEMA Co. public comparables operate across Health & Beauty, Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
CROSSJECT7.7x3.8x(19.0x)11.6x
Neuronetics1.2x1.2x(8.6x)(10.9x)
Optiscan Imaging153.0x-(25.0x)-
Paxman3.0x2.6x32.8x18.8x
Vivani Medical--(4.1x)-
Medifast(0.1x)(0.1x)(5.2x)(16.1x)
IEVA Group2.0x2.4x(299.3x)(157.4x)
Beauty Health----

This data is available for Pro users. Sign up to see all JETEMA Co. competitors and their valuation data.

Start Free Trial

Investments by JETEMA Co.

JETEMA Co. has invested in 2 companies to date.

Latest investment by JETEMA Co. was on June 27th 2024. JETEMA Co. invested in Morpheus3d in their $2M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by JETEMA Co.

Morpheus3d
Feroka
Description
Morpheus3d is a South Korea-based manufacturer of 3D-printed medical devices and surgical guides for orthopedic and dental procedures. Established in 2017 in Seoul, it produces patient-specific implants using titanium alloys and biocompatible resins for hospitals including Samsung Medical Center. Morpheus3d certifies products under KFDA standards with exports to Japan and Southeast Asia.
Feroka is a South Korea-based biotech company developing dissolvable microneedle patch technology for targeted drug delivery. The platform enables precise dosing to epidermis or dermis layers for vaccines, cosmetics, and therapeutics. Patches feature a melting shaft for painless application and easy removal. Headquartered in Seoul and founded in 2020, Feroka collaborates with pharmaceutical firms on clinical trials for dermatology and pain management applications.
HQ CountrySouth KoreaSouth Korea
HQ City
Suwon
Seoul
Deal Date27 Jun 202424 Aug 2022
RoundStrategic investmentSeries B
Raised$2M$8M
InvestorsJETEMA Co.Welcome Capital; HB Investment; IBK Capital; JETEMA Co.
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all JETEMA Co. investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About JETEMA Co.

When was JETEMA Co. founded?JETEMA Co. was founded in 2009.
Where is JETEMA Co. headquartered?JETEMA Co. is headquartered in South Korea.
Is JETEMA Co. publicly listed?Yes, JETEMA Co. is a public company listed on Korea Exchange.
What is the stock symbol of JETEMA Co.?JETEMA Co. trades under 216080 ticker.
When did JETEMA Co. go public?JETEMA Co. went public in 2019.
Who are competitors of JETEMA Co.?JETEMA Co. main competitors include CROSSJECT, Neuronetics, Optiscan Imaging, Paxman, Vivani Medical, Medifast, IEVA Group, Beauty Health, Emvision, Onyx Healthcare.
What is the current market cap of JETEMA Co.?JETEMA Co.'s current market cap is $111M.
What is the current revenue of JETEMA Co.?JETEMA Co.'s last fiscal year revenue is $52M.
What is the current revenue growth of JETEMA Co.?JETEMA Co. revenue growth (vs. last FY) is 18%.
What is the current EV/Revenue multiple of JETEMA Co.?Current revenue multiple of JETEMA Co. is 3.6x.
Is JETEMA Co. profitable?No, JETEMA Co. is not profitable.
How many companies JETEMA Co. has acquired to date?JETEMA Co. hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies JETEMA Co. has invested to date?As of July 2026, JETEMA Co. has invested in 2 companies.
What was the last JETEMA Co. investment?On 27th June 2024 JETEMA Co. invested in Morpheus3d, participating in a $2M Strategic investment round.
In what companies JETEMA Co. invested in?JETEMA Co. invested in Feroka and Morpheus3d.

See public comps similar to JETEMA Co.

Lists including JETEMA Co.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial